Search results for "Pharmacokinetics"

showing 10 items of 458 documents

Problem solving in psychopharmacotherapy using pharmacokinetic and pharmacogenetic tests

2007

Many problems such as non-response, pharmacokinetic interactions with clinical consequences and adverse effects (pharmacovigilance) may be observed in patients submitted to psychopharmacotherapy. These risks are increased in patients belonging to the category of “special populations”: elderly patients, children and adolescents, patients with a genetic particularity of metabolism or suffering from somatic or psychic comorbidities. Pharmacokinetic and pharmacogenetic tests are useful to solve problems in psychopharmacotherapy and thus improve efficacy and safety. Therapeutic drug monitoring (TDM) is particularly recommended in situations presented above and in patients who are non-compliant. …

medicine.medical_specialtySpecial populationsmedicine.diagnostic_testbusiness.industryTreatment outcomePsychiatry and Mental healthPharmacokineticsTherapeutic drug monitoringPharmacovigilancemedicineIn patientIntensive care medicinebusinessAdverse effectPharmacogeneticsEuropean Psychiatry
researchProduct

Elimination of hexamethylene diisocyanate cross-linked polypeptides in patients with normal or impaired renal function

1978

Infusions of 3.5% isocyanate cross-linked polypeptide solution 500 ml were given to 52 patients with normal or impaired renal function: glomerular filtration rate (GFR)=0–133 ml/min. The serum concentration and urinary excretion of hydroxyproline were measured and the equivalent polypeptide concentrations were calculated from the results. In patients with normal renal function (GFR>90 ml/min) the proportion of polypeptide excreted in the urine up to 12 h was 45.4±2.6% ( $$\bar X$$ ±SEM), up to 24 h 47.7±2.9% and up to 48 h 49.3±3.4%. In patients with moderate renal insufficiency (GFR=30–90 ml/min) there was no decrease in polypeptide excretion and even in patients with more serious impairme…

medicine.medical_specialtyTime FactorsUrinary systemPlasma SubstitutesRenal functionUrine030204 cardiovascular system & hematologyurologic and male genital diseasesExcretion03 medical and health sciencesHydroxyprolinechemistry.chemical_compound0302 clinical medicinePharmacokineticsRenal Dialysis030202 anesthesiologyInternal medicinemedicineHumansPharmacology (medical)CyanatesPharmacologyChemistryHalf-lifeGeneral Medicine3. Good healthKineticsEndocrinologyKidney DiseasesPeptidesHaemaccelGlomerular Filtration RateHalf-LifeEuropean Journal of Clinical Pharmacology
researchProduct

Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.

2011

Introduction: Pemphigus is an autoimmune blistering disease of the skin and mucous membranes characterized by the development of autoantibodies against the desmosomal proteins, desmoglein-1 and -3. Before the advent of corticosteroids, therapy was almost fatal. The introduction of high-dose corticosteroid therapy has reduced mortality rates to similar to 10%, but long-term use of steroids can lead to side effects, many of which are severe and associated with significant morbidity. Thus, the major goal of pemphigus therapy has been to reduce the patient's cumulative exposure to systemic corticosteroids. Over the last 2 decades, a range of corticosteroid-sparing immunosuppressive agents have …

medicine.medical_specialtyToxicologyMycophenolateMycophenolic acidPharmacokineticsAdrenal Cortex HormonesmedicineInitial treatmentimmunosuppressant inosine monophosphate dehydrogenase mycophenolate mofetil mycophenolic acid pemphigus pharmacokinetic treatmentHumansPharmacologyintegumentary systembusiness.industryMortality rateAutoantibodyGeneral MedicineMycophenolic Acidmedicine.diseaseDermatologyPemphigusImmunologybusinessImmunosuppressive AgentsPemphigusmedicine.drugBlistering diseaseExpert opinion on drug metabolismtoxicology
researchProduct

External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical set…

2013

Vancomycin is one of the most evaluated antibiotics in neonates using modeling and simulation approaches. However no clear consensus on optimal dosing has been achieved. The objective of the present study was to perform an external evaluation of published models, in order to test their predictive performances in an independent dataset and to identify the possible study-related factors influencing the transferability of pharmacokinetic models to different clinical settings. Published neonatal vancomycin pharmacokinetic models were screened from the literature. The predictive performance of 6 models was evaluated using an independent dataset (112 concentrations from 78 neonates). The evaluati…

medicine.medical_specialtyTransferabilityPopulationClinical settings030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsInternal medicinemedicinePharmacology (medical)DosingeducationIntensive care medicinePharmacology0303 health sciencesCreatinineeducation.field_of_study030306 microbiologybusiness.industry3. Good healthchemistryPredictive value of testsVancomycinbusinessmedicine.drugBritish Journal of Clinical Pharmacology
researchProduct

Clinical and Epidemiological Study on Patients with Mandibular Fractures within the Oral and Maxillofacial Surgery Compartment in the Sibiu County Cl…

2019

Abstract Traumatology from the oral and maxillofacial area represents a very important and frequent pathology within this specialty, the mandibular fractures occupying the first place in terms of location and frequency due to the anatomical prominent position of the mandible. The first three etiological factors are represented by aggressions, accidental falls and car accidents. This article, accomplished in collaboration with the statistical service of the Sibiu County Clinical Emergency Hospital, aims at analysing the distribution by sex, origin environments, levels of studies, presentation of patients, analysis which was broken down by days of the week, frequent symptoms of these types of…

medicine.medical_specialtybusiness.industryGeneral surgeryEpidemiologymedicineOral and maxillofacial surgeryPrevalenceEtiologyGeneral MedicineCompartment (pharmacokinetics)businessActa Medica Transilvanica
researchProduct

Single Intravenous Dose Kinetics and Accumulation of Atenolol in Patients with Impaired Renal Function and on Hemodialysis

1980

The concentration of atenolol in plasma and urine was determined following an intravenous (i.v.) dose given to 17 hypertensive patients with a glomerular filtration rate (GFR) between 5 and 105 ml/min and in 4 patients on hemodialysis. In patients with normal renal function the mean half life of elimination was calculated to be 6.8 h. This value increased to a mean of 50.1 h in patients with a GFR below 10 ml/min. In patients on hemodialysis the half life of elimination was about 4 h. The elimination rate constants as well as the body and renal clearances of atenolol have a significant correlation with the GFR. Although accumulation of atenolol was observed, especially after multiple oral d…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentUrologyHalf-lifeRenal functionUrineurologic and male genital diseasesAtenololImpaired renal functionPharmacokineticsmedicineIn patientHemodialysisbusinessmedicine.drug
researchProduct

INT-009 Pharmacokinetics of linezolid and meropenem in intensive care unit patients receiving continuous renal replacement therapy

2016

Background Intensive care unit (ICU) patients often suffer from infections and acute renal failure and might need continuous renal replacement therapy commonly applied by veno-venous hemodialysis (CVVHD) or hemodiafiltration (CVVHDF). In this case there are no dosage recommendations in the product informations of antibiotics and literature data are scarce. The risk for therapy failure, development of resistance and adverse drug effects is elevated. Purpose Aim of the presented study was to find out if standard therapy of Linezolid (LZ) and Meropenem (MP) results in adequate plasma levels in surgical ICU patients receiving CVVHD(F). Materials and Methods Surgical ICU patients receiving CVVHD…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.drug_classmedicine.medical_treatmentAntibioticsMeropenemIntensive care unitSurgerylaw.inventionchemistry.chemical_compoundchemistryPharmacokineticslawTherapeutic drug monitoringAnesthesiaLinezolidmedicineRenal replacement therapyHemodialysisGeneral Pharmacology Toxicology and Pharmaceuticsbusinessmedicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

Clinical pharmacokinetics of atenolol — A review

1982

Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. After oral administration atenolol is incompletely absorbed from the intestine, so about 50% of the beta blocker are finally biovailable. In plasma only 3% of atenolol are protein-bound. There exists a linear relationship between the atenolol plasma levels and the degree of beta blocking effect measured by inhibition of the exercise-induced tachycardia. No correlation was found between plasma levels of atenolol and blood pressure lowering activity of the drug. After oral administration elimination half life of atenolol is calcula…

medicine.medical_specialtymedicine.drug_classAdministration OralBiological AvailabilityRenal functionPharmacologyKidneyIntestinal absorptionPropanolaminesPharmacokineticsRenal DialysisOral administrationInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)cardiovascular diseasesBeta blockerPharmacologyChemistryLiver DiseasesKidney metabolismAtenololKineticsEndocrinologyAtenololIntestinal AbsorptionInjections IntravenousKidney DiseasesBiological half-lifecirculatory and respiratory physiologymedicine.drugEuropean Journal of Drug Metabolism and Pharmacokinetics
researchProduct

Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry

2021

Thrombosis and haemostasis 122(4), 552-559 (2022). doi:10.1055/a-1549-6556

medicine.medical_specialtymedicine.drug_classPyridonesAdministration OralHemorrhagePharmacokineticsRivaroxabanInternal medicineAtrial FibrillationmedicineHumansProspective StudiesRegistriesRivaroxabanbusiness.industryAnticoagulantAnticoagulantsHematologyEmergency situationsConfidence intervalDabigatranClinical trialApixabanObservational studybusinessmedicine.drug
researchProduct

Pharmacokinetic Study on Adenomatous Prostate Tissue Concentrations of Cef operazone

1989

Cephalosporins do not reach active therapeutical concentrations in the prostatic tissue in patients suffering from chronic bacterial prostatitis. Cefoperazone is an exception. Its efficacy in the trea

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAntibioticsCephalosporinProstatitisGastroenterologyPharmacokineticsProstateInternal medicineDrug DiscoverymedicinePharmacology (medical)PharmacologyChemotherapybusiness.industryGeneral Medicinemedicine.diseaseCefoperazoneInfectious Diseasesmedicine.anatomical_structureChronic bacterial prostatitisOncologyImmunologybusinessmedicine.drugChemotherapy
researchProduct